{"entity":{"id":"paper-invictus-ripretinib-lancet-oncol-2020","kind":"paper","name":"INVICTUS: ripretinib in advanced gastrointestinal stromal tumours after three or more prior kinase inhibitors","aka":[],"tldr":"The switch-control KIT inhibitor ripretinib lengthened progression-free survival from one to six months and improved survival compared with placebo in gastrointestinal stromal tumours that had failed imatinib, sunitinib and regorafenib.","summary":"Phase 3 placebo-controlled trial of 129 patients with advanced GIST after at least three prior kinase inhibitors randomised 2:1 to ripretinib 150 mg daily or placebo with crossover.\n\nMedian progression-free survival was 6.3 versus 1.0 months (hazard ratio 0.15) and median overall survival 15.1 versus 6.6 months (hazard ratio 0.36); alopecia, myalgia and hand-foot syndrome were common and mostly low grade.","asOf":"2026-09-17","links":[{"label":"Lancet Oncol 2020","url":"https://doi.org/10.1016/S1470-2045(20)30168-6"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/32511981/"}],"tags":[],"related":[],"cancers":["gist-imatinib-resistant"],"sections":[],"technologies":[],"targets":[],"drugs":["ripretinib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["invictus"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["lancet-oncology"],"dependsOn":[],"notes":[],"journal":"The Lancet Oncology","year":2020,"doi":"10.1016/S1470-2045(20)30168-6","pmid":"32511981","authors":"Blay JY, Serrano C, Heinrich MC, et al.","paperType":"rct","findings":["Median progression-free survival 6.3 vs 1.0 months; hazard ratio 0.15.","Median overall survival 15.1 vs 6.6 months; hazard ratio 0.36."],"whatItMeans":"Ripretinib is the approved fourth-line treatment for GIST and is being tested earlier in mutation-selected patients (INSIGHT).","caveats":["Objective response was only 9 percent; benefit is disease stabilisation.","Small trial in a heavily pretreated population."],"changedPractice":true,"participants":129},"route":"/key-papers/paper-invictus-ripretinib-lancet-oncol-2020/","neighbours":{"cancer":[{"id":"gist-imatinib-resistant","kind":"cancer","name":"Imatinib-resistant GIST","route":"/cancers/gist-imatinib-resistant/"}],"drug":[{"id":"ripretinib","kind":"drug","name":"Ripretinib","route":"/drugs/ripretinib/"}],"trial":[{"id":"invictus","kind":"trial","name":"INVICTUS","route":"/trials/invictus/"}],"journal":[{"id":"lancet-oncology","kind":"journal","name":"The Lancet Oncology","route":"/journals/lancet-oncology/"}]}}